A pharmaceutical version of a compound may be FDA-approved even when the research-grade version is not. That approval applies to the specific drug product, its dosage form, its manufacturing pathway, and its labeled medical indication — not to every vial or every research supplier using the same molecule name.

OSYRIS products are not those pharmaceutical brands. They are research-grade compounds sold for laboratory research only. The table below is included for regulatory context, not as a claim of equivalence.

FDA approval of a pharmaceutical equivalent does not automatically convert a research-grade product into a legal prescription drug, a compounded medication, or a therapeutically marketed product. It also does not remove the RUO framework that applies to research-only sales.

Compounds like retatrutide add another layer: promising clinical data may exist even before formal approval. That can matter for research interest and literature depth, but it is still not the same thing as FDA approval.